What is the recommended first-line anti-epileptic drug for a 15-year-old girl newly diagnosed with juvenile myoclonic epilepsy?
Q22
A 14-year-old boy with type 1 diabetes for 5 years uses a basal-bolus insulin regimen. Despite regular clinic attendance, his HbA1c has been consistently between 75-82 mmol/mol over the past 18 months. His diabetes team notes he frequently misses morning blood glucose checks and often forgets his lunchtime insulin at school. During consultation, he admits feeling embarrassed about having diabetes in front of his peers and sometimes skips insulin doses to avoid attention. What is the most appropriate initial management approach to improve his glycaemic control?
Q23
A 5-year-old girl presents to the emergency department with her first unprovoked seizure. She had a 3-minute episode of right arm jerking that progressed to right leg involvement, with preserved consciousness throughout. After the seizure, she had weakness of the right arm and leg lasting 45 minutes before full recovery. There is no fever, and she is systemically well. Neurological examination is now normal. What investigation finding would most strongly support a diagnosis of benign epilepsy with centrotemporal spikes (benign rolandic epilepsy)?
Q24
A 9-year-old girl with a 4-year history of epilepsy controlled on sodium valproate presents for routine follow-up. Her mother reports that over the past 6 months, the girl has gained significant weight (BMI increased from 50th to 91st centile), developed increased facial hair, and has irregular periods since menarche 8 months ago. Blood tests reveal: testosterone elevated, LH:FSH ratio 3:1, fasting glucose 5.2 mmol/L, and normal thyroid function. Pelvic ultrasound shows multiple peripheral ovarian follicles bilaterally. What is the most appropriate next step in management?
Q25
A 6-year-old boy with type 1 diabetes mellitus is being transitioned from multiple daily injections to continuous subcutaneous insulin infusion (insulin pump therapy). His parents ask about the primary advantage of this treatment modality. What is the most important benefit of insulin pump therapy compared to multiple daily injections in children with type 1 diabetes?
Q26
A 16-year-old boy with type 1 diabetes for 9 years attends for annual screening. He reports occasional paraesthesia in his feet. Monofilament testing shows reduced sensation in both feet in a stocking distribution. Ankle reflexes are absent bilaterally. Vibration sense is reduced to the level of the malleoli. HbA1c is 82 mmol/mol (9.7%). Urinalysis shows no proteinuria. What is the most appropriate initial investigation to confirm the suspected diagnosis?
Q27
An 8-year-old boy with epilepsy presents to the emergency department with ataxia, nystagmus, and diplopia. He has been taking phenytoin for focal seizures with good control for 18 months. His mother mentions she recently increased his dose because he had a breakthrough seizure last week. Blood tests show phenytoin level of 32 mg/L (therapeutic range 10-20 mg/L), albumin 38 g/L, urea 5.2 mmol/L, creatinine 52 μmol/L. What characteristic of phenytoin pharmacokinetics most likely contributed to this presentation?
Q28
A 11-year-old boy with type 1 diabetes for 4 years uses an insulin pump delivering a total daily dose of 32 units. His basal rates are appropriately configured. He is about to eat lunch containing 60 grams of carbohydrate. His pre-lunch blood glucose is 13.2 mmol/L and his target is 6.0 mmol/L. His insulin-to-carbohydrate ratio is 1:15 and his insulin sensitivity factor is 1 unit lowers glucose by 3 mmol/L. What is the correct total bolus insulin dose?
Q29
A 15-year-old girl with juvenile myoclonic epilepsy controlled on sodium valproate 800 mg twice daily for 3 years is seen in clinic. She has been seizure-free for 2 years. She mentions she is sexually active and wants to discuss contraception. Her weight is 68 kg and BMI is 24 kg/m². She has no other medical conditions. What is the most appropriate advice regarding contraception?
Q30
A 4-year-old boy with newly diagnosed type 1 diabetes is being started on insulin therapy. His weight is 16 kg. The diabetes team plans to commence a basal-bolus regimen. Using a standard starting total daily insulin dose of 0.5 units/kg/day, with 50% as basal insulin and 50% divided between three meals, what is the appropriate starting dose of rapid-acting insulin for each main meal?
Chronic Paediatric Conditions UK Medical PG Practice Questions and MCQs
Question 21: What is the recommended first-line anti-epileptic drug for a 15-year-old girl newly diagnosed with juvenile myoclonic epilepsy?
A. Sodium valproate
B. Levetiracetam (Correct Answer)
C. Carbamazepine
D. Phenytoin
E. Ethosuximide
Explanation: ***Levetiracetam***
- In females of **childbearing potential**, levetiracetam is the preferred first-line agent for **Juvenile Myoclonic Epilepsy (JME)** due to a lower risk of **teratogenicity**.
- It provides effective seizure control across the spectrum of seizure types in JME, including **myoclonic jerks** and generalized tonic-clonic seizures.
*Sodium valproate*
- While traditionally the most effective drug for JME, it is now **contraindicated** in females of childbearing age unless a strict **Pregnancy Prevention Programme** is in place.
- Significant risks include **neural tube defects**, neurodevelopmental delay, and **polycystic ovary syndrome (PCOS)**.
*Carbamazepine*
- This drug is narrow-spectrum and can **paradoxically worsen** myoclonic and absence seizures in patients with generalized epilepsies like JME.
- It is primarily indicated for **focal seizures**, and its use in JME can lead to an increase in seizure frequency.
*Phenytoin*
- Similar to carbamazepine, phenytoin can **exacerbate myoclonic jerks** and absence seizures in primary generalized epilepsy syndromes.
- It is not recommended for JME and is associated with long-term side effects like **gingival hyperplasia** and hirsutism.
*Ethosuximide*
- This agent is specifically used for **absence seizures** and lacks efficacy against the **myoclonic jerks** and generalized tonic-clonic seizures characteristic of JME.
- It would leave the patient at high risk for major motor seizures if used as monotherapy in this clinical scenario.
Question 22: A 14-year-old boy with type 1 diabetes for 5 years uses a basal-bolus insulin regimen. Despite regular clinic attendance, his HbA1c has been consistently between 75-82 mmol/mol over the past 18 months. His diabetes team notes he frequently misses morning blood glucose checks and often forgets his lunchtime insulin at school. During consultation, he admits feeling embarrassed about having diabetes in front of his peers and sometimes skips insulin doses to avoid attention. What is the most appropriate initial management approach to improve his glycaemic control?
A. Switch to twice-daily premixed insulin to simplify his regimen and improve compliance
B. Arrange urgent psychology referral to address his emotional wellbeing and coping strategies (Correct Answer)
C. Increase basal insulin dose by 20% to compensate for missed bolus doses
D. Commence continuous glucose monitoring and insulin pump therapy to reduce daily burden
E. Involve school nurse to administer all insulin doses during school hours
Explanation: ***Arrange urgent psychology referral to address his emotional wellbeing and coping strategies***
- The patient admits to **intentional insulin omission** due to **diabetes-related distress** and peer embarrassment, which are primary psychological barriers to management.
- Addressing the **psychosocial impact** of a chronic condition during adolescence is critical to improving adherence and long-term glycemic control.
*Switch to twice-daily premixed insulin to simplify his regimen and improve compliance*
- While this simplifies the schedule, it offers significantly less **glycaemic flexibility** and does not address the underlying **psychological distress** regarding peer perception.
- **Premixed insulin** is generally not recommended as a first-line alternative for active adolescents who require the precision of basal-bolus therapy.
*Increase basal insulin dose by 20% to compensate for missed bolus doses*
- Increasing **basal insulin** to cover missed bolus doses is clinically unsafe and significantly increases the risk of severe **hypoglycaemia**, especially during fasting periods or exercise.
- It fails to address the behavioral issue of **missed lunchtime boluses** and avoids the root cause of the patient's non-adherence.
*Commence continuous glucose monitoring and insulin pump therapy to reduce daily burden*
- **Insulin pump therapy** and **CGM** can increase the visibility of the condition, potentially worsening the patient's feelings of **embarrassment** or being "different."
- Advanced technology requires high levels of **engagement** and motivation, which may be absent until the patient's emotional barriers are addressed.
*Involve school nurse to administer all insulin doses during school hours*
- This approach may further undermine the patient's **autonomy** and increase the feeling of being singled out, potentially exacerbating his **social anxiety**.
- It provides a temporary fix for dosing but does not help the adolescent develop the necessary **coping strategies** for self-management as he transitions to adulthood.
Question 23: A 5-year-old girl presents to the emergency department with her first unprovoked seizure. She had a 3-minute episode of right arm jerking that progressed to right leg involvement, with preserved consciousness throughout. After the seizure, she had weakness of the right arm and leg lasting 45 minutes before full recovery. There is no fever, and she is systemically well. Neurological examination is now normal. What investigation finding would most strongly support a diagnosis of benign epilepsy with centrotemporal spikes (benign rolandic epilepsy)?
A. MRI brain showing focal cortical dysplasia in the left frontal lobe
B. CT brain revealing left hemisphere hemiatrophy
C. EEG with hypsarrhythmia pattern
D. EEG demonstrating 3 Hz spike-and-wave discharges activated by hyperventilation
E. EEG showing centrotemporal spikes that increase in frequency during sleep (Correct Answer)
Explanation: ***EEG showing centrotemporal spikes that increase in frequency during sleep***
- The hallmark of **Benign Rolandic Epilepsy (BECTS)** is the presence of high-amplitude **centrotemporal (rolandic) spikes**, which characteristically become more frequent during **non-REM sleep**.
- This patient's presentation of a **focal motor seizure** with subsequent **Todd’s paresis** (transient weakness) in a healthy 5-year-old child is classic for this self-limiting syndrome.
*MRI brain showing focal cortical dysplasia in the left frontal lobe*
- Findings of **focal cortical dysplasia** indicate **structural epilepsy**, which is typically associated with more refractory seizures and requires surgical consideration.
- **Benign Rolandic Epilepsy** is an idiopathic syndrome where neuroimaging is characteristically **normal**.
*CT brain revealing left hemisphere hemiatrophy*
- **Hemiatrophy** of a cerebral hemisphere is indicative of chronic injury or syndromes like **Davidoff-Mason** or **Sturge-Weber**, not a benign epilepsy syndrome.
- This child had a **normal neurological examination** after the post-ictal phase, which makes significant structural atrophy highly unlikely.
*EEG with hypsarrhythmia pattern*
- **Hypsarrhythmia** is the chaotic, high-voltage EEG pattern seen in **West Syndrome** (infantile spasms).
- This pattern is seen in **infants** (typically 4–8 months old) and is associated with **developmental regression**, unlike the focal motor seizures seen in this 5-year-old.
*EEG demonstrating 3 Hz spike-and-wave discharges activated by hyperventilation*
- This EEG pattern is pathognomonic for **Childhood Absence Epilepsy**, which presents with brief **staring spells** and loss of awareness.
- **Absence epilepsy** does not typically feature focal motor jerking or **post-ictal weakness (Todd's paresis)** as described in this case.
Question 24: A 9-year-old girl with a 4-year history of epilepsy controlled on sodium valproate presents for routine follow-up. Her mother reports that over the past 6 months, the girl has gained significant weight (BMI increased from 50th to 91st centile), developed increased facial hair, and has irregular periods since menarche 8 months ago. Blood tests reveal: testosterone elevated, LH:FSH ratio 3:1, fasting glucose 5.2 mmol/L, and normal thyroid function. Pelvic ultrasound shows multiple peripheral ovarian follicles bilaterally. What is the most appropriate next step in management?
A. Switch sodium valproate to levetiracetam and provide lifestyle advice (Correct Answer)
B. Commence oral contraceptive pill to regulate menstrual cycles
C. Refer to paediatric endocrinology for further investigation of hyperandrogenism
D. Reduce the dose of sodium valproate by 50% and monitor
E. Add metformin to address insulin resistance and continue valproate
Explanation: ***Switch sodium valproate to levetiracetam and provide lifestyle advice***
- **Sodium valproate** is strongly associated with **weight gain**, **hyperandrogenism**, and the development of **polycystic ovary syndrome (PCOS)**-like features in adolescent girls and women.
- Replacing valproate with an alternative like **levetiracetam** is the definitive management step to reverse metabolic side effects and comply with safety guidelines for females of childbearing potential, complemented by **lifestyle advice** for weight management.
*Commence oral contraceptive pill to regulate menstrual cycles*
- While the **oral contraceptive pill (OCP)** can manage symptoms like irregular periods and hirsutism, it does not address the **underlying metabolic cause** triggered by valproate.
- Using OCPs as a primary solution without stopping the causative medication ignores the ongoing risk of **teratogenicity** and potential worsening of **weight gain** associated with valproate.
*Refer to paediatric endocrinology for further investigation of hyperandrogenism*
- Referral is generally unnecessary as the clinical presentation and history of **valproate use** clearly identify the medication as the primary cause of the **PCOS-like features** (weight gain, hirsutism, elevated testosterone, LH:FSH ratio, polycystic ovaries).
- Management of medication-induced hormonal changes should first involve **adjusting the epilepsy treatment** in coordination with a neurologist, rather than seeking further diagnostic investigations.
*Reduce the dose of sodium valproate by 50% and monitor*
- Reducing the dose is often insufficient to reverse **metabolic and endocrine side effects** fully, and it risks the loss of **seizure control** if the therapeutic threshold is not maintained.
- Guidelines recommend **completely avoiding or switching** from valproate in girls and women unless no other alternative exists due to the severe **teratogenic** and endocrine risks, making a dose reduction suboptimal.
*Add metformin to address insulin resistance and continue valproate*
- **Metformin** may improve insulin sensitivity, but it is not the standard of care for treating **drug-induced PCOS** when a safer anticonvulsant alternative is readily available.
- Continuing valproate while adding polypharmacy increases the **side effect burden** and fails to remove the primary stimulus for weight gain, hyperandrogenism, and the significant **teratogenic risk**.
Question 25: A 6-year-old boy with type 1 diabetes mellitus is being transitioned from multiple daily injections to continuous subcutaneous insulin infusion (insulin pump therapy). His parents ask about the primary advantage of this treatment modality. What is the most important benefit of insulin pump therapy compared to multiple daily injections in children with type 1 diabetes?
A. Elimination of the need for blood glucose monitoring
B. Reduced frequency of injection site complications such as lipohypertrophy
C. More physiological insulin delivery with precise basal rate adjustments (Correct Answer)
D. Lower overall daily insulin requirements
E. Complete prevention of hypoglycaemic episodes
Explanation: ***More physiological insulin delivery with precise basal rate adjustments***- Insulin pumps allow for programmable **basal rates** that can be adjusted in very small increments to match the child's fluctuating daily needs, such as the **dawn phenomenon** or physical activity.- This modality mimics the **pancreatic secretion** of insulin more closely than long-acting injections, providing significantly more flexibility in lifestyle and meal planning.*Elimination of the need for blood glucose monitoring*- Insulin pump therapy actually necessitates **more frequent monitoring** or the use of **continuous glucose monitoring (CGM)** to ensure safety and dose accuracy.- Monitoring is critical to detect **catheter occlusions** early, which can rapidly lead to diabetic ketoacidosis due to the lack of long-acting insulin depot.*Reduced frequency of injection site complications such as lipohypertrophy*- While it reduces the number of daily punctures, the **cannula** remains in place for 2-3 days, which can still cause skin irritation or **lipohypertrophy** if sites are not rotated.- Site-related issues like **infections or abscesses** are specifically associated with continuous infusion sets if hygiene or rotation is neglected.*Lower overall daily insulin requirements*- While some patients may see a slight reduction in total units due to improved absorption, a **lower insulin dose** is not the primary clinical goal or advantage of switching to a pump.- The priority remains achieving **glycemic targets** and reducing variability rather than simply minimizing the quantity of insulin used.*Complete prevention of hypoglycaemic episodes*- While pumps can help reduce the frequency of severe events through **precise dosing**, they cannot **completely prevent** hypoglycemia caused by exercise or dosing errors.- The risk of **hypoglycemia** remains present, requiring the patient and caregivers to maintain vigilance and carry fast-acting glucose at all times.
Question 26: A 16-year-old boy with type 1 diabetes for 9 years attends for annual screening. He reports occasional paraesthesia in his feet. Monofilament testing shows reduced sensation in both feet in a stocking distribution. Ankle reflexes are absent bilaterally. Vibration sense is reduced to the level of the malleoli. HbA1c is 82 mmol/mol (9.7%). Urinalysis shows no proteinuria. What is the most appropriate initial investigation to confirm the suspected diagnosis?
A. Nerve conduction studies (Correct Answer)
B. Quantitative sensory testing
C. Skin biopsy for intraepidermal nerve fibre density
D. Sural nerve biopsy
E. MRI of lumbar spine
Explanation: ***Nerve conduction studies***- **Nerve conduction studies (NCS)** are the gold standard initial investigation to objectively confirm the diagnosis of **diabetic peripheral neuropathy**, especially large-fiber involvement indicated by absent ankle reflexes and reduced vibration sense.- They provide objective data on nerve function, allowing assessment of **nerve conduction velocity** and **amplitude**, which are typically reduced in diabetic neuropathy due to axonal loss and demyelination.*Quantitative sensory testing*- This method is primarily a **subjective test** used to quantify sensory thresholds (e.g., vibration, temperature), often employed in research settings rather than as a primary diagnostic tool for typical diabetic neuropathy.- It relies heavily on patient cooperation and perception, making it less objective and reliable than electrophysiological studies for initial confirmation of nerve damage.*Skin biopsy for intraepidermal nerve fibre density*- This investigation is specific for diagnosing **small-fiber neuropathy** by quantifying nerve fiber density in the epidermis.- It is generally considered when clinical suspicion of neuropathy is high but standard **nerve conduction studies are normal**, as small fibers are not assessed by NCS and symptoms here suggest large fiber involvement (absent reflexes).*Sural nerve biopsy*- This is an **invasive procedure** involving the removal of a nerve sample, typically reserved for atypical or rapidly progressive neuropathies where specific causes like **vasculitis**, amyloidosis, or inflammatory demyelinating conditions are suspected.- It is rarely performed for uncomplicated **diabetic peripheral neuropathy** due to its invasiveness and the typical clarity of diagnosis with less invasive methods.*MRI of lumbar spine*- An **MRI of the lumbar spine** is primarily used to investigate **spinal cord compression**, radiculopathy, or other structural pathologies affecting the spinal nerves.- The patient's symptoms (stocking distribution sensory loss, absent ankle reflexes, reduced vibration sense) are characteristic of a **generalized peripheral polyneuropathy** rather than a focal spinal issue.
Question 27: An 8-year-old boy with epilepsy presents to the emergency department with ataxia, nystagmus, and diplopia. He has been taking phenytoin for focal seizures with good control for 18 months. His mother mentions she recently increased his dose because he had a breakthrough seizure last week. Blood tests show phenytoin level of 32 mg/L (therapeutic range 10-20 mg/L), albumin 38 g/L, urea 5.2 mmol/L, creatinine 52 μmol/L. What characteristic of phenytoin pharmacokinetics most likely contributed to this presentation?
A. Linear pharmacokinetics throughout therapeutic range
B. Zero-order kinetics at higher doses (Correct Answer)
C. Extensive first-pass hepatic metabolism
D. High degree of plasma protein binding
E. Rapid renal clearance
Explanation: ***Zero-order kinetics at higher doses***
- Phenytoin exhibits **saturation kinetics**, where metabolic enzymes (CYP2C9/19) become saturated at or just above the therapeutic range, switching from first-order to **zero-order kinetics**.
- This means a **fixed amount** of drug is eliminated per unit time, so small dose increases can lead to **disproportionately large increases** in plasma concentration and clinical toxicity (ataxia, nystagmus).
*Linear pharmacokinetics throughout therapeutic range*
- Linear or **first-order kinetics** involve elimination of a constant fraction of the drug, which would result in predictable, proportional level increases.
- Phenytoin is unique because it specifically lacks **linear pharmacokinetics** at higher therapeutic concentrations, making its dosing dangerous without monitoring.
*Extensive first-pass hepatic metabolism*
- **First-pass metabolism** affects bioavailability (the amount of drug reaching systemic circulation) after oral administration but does not explain toxicity from a dose increase in a stable patient.
- Phenytoin actually has **good oral bioavailability**, and its toxicity is driven by elimination failure due to enzyme saturation, not initial metabolism.
*High degree of plasma protein binding*
- While phenytoin is **90% protein-bound** to albumin, this property usually causes toxicity issues during **hypoalbuminemia** or drug displacements, which are not present here (albumin is normal).
- **Protein binding** does not explain why a simple dose increase would lead to such a massive rise in serum levels compared to saturation kinetics.
*Rapid renal clearance*
- Phenytoin is primarily eliminated via **hepatic metabolism** to inactive metabolites, not through **rapid renal clearance**.
- Only a very small percentage of phenytoin is excreted unchanged in the urine; therefore, renal function has a minimal impact on its primary clearance pathway.
Question 28: A 11-year-old boy with type 1 diabetes for 4 years uses an insulin pump delivering a total daily dose of 32 units. His basal rates are appropriately configured. He is about to eat lunch containing 60 grams of carbohydrate. His pre-lunch blood glucose is 13.2 mmol/L and his target is 6.0 mmol/L. His insulin-to-carbohydrate ratio is 1:15 and his insulin sensitivity factor is 1 unit lowers glucose by 3 mmol/L. What is the correct total bolus insulin dose?
A. 4 units
B. 6.4 units (Correct Answer)
C. 8 units
D. 10.4 units
E. 12 units
Explanation: ***6.4 units***- The total bolus dose is calculated by adding the **carbohydrate dose** (60g / 15 = **4 units**) and the **correction dose** ((13.2 mmol/L - 6.0 mmol/L) / 3 = **2.4 units**).- Summing these components (4 + 2.4) results in a total of **6.4 units**, representing the accurate insulin needed to cover both the meal and the hyperglycemia.*4 units*- This value represents only the **carbohydrate coverage** (60 / 15) without addressing the patient's elevated **pre-meal blood glucose**.- Using this dose would leave the glucose level significantly above the **target of 6.0 mmol/L**.*8 units*- This incorrect value likely stems from a calculation error in the **insulin sensitivity factor** or the **carbohydrate ratio**.- It does not follow the medical formula for combining **bolus insulin** and **correction factors** provided in the clinical data.*10.4 units*- This dose is an **overestimate** that could lead to severe **hypoglycemia** in an 11-year-old patient.- It may occur if the **total daily dose** (32 units) is incorrectly utilized in the formula instead of the specific ratios provided.*12 units*- This value is significantly higher than required and suggests a fundamental error in applying the **1:15 carbohydrate ratio**.- Routine administration of incorrect doses of this magnitude poses a high risk for **iatrogenic hypoglycemic events**.
Question 29: A 15-year-old girl with juvenile myoclonic epilepsy controlled on sodium valproate 800 mg twice daily for 3 years is seen in clinic. She has been seizure-free for 2 years. She mentions she is sexually active and wants to discuss contraception. Her weight is 68 kg and BMI is 24 kg/m². She has no other medical conditions. What is the most appropriate advice regarding contraception?
A. Combined oral contraceptive pill is safe and effective
B. Progesterone-only pill will provide adequate contraception
C. Intrauterine device is the most appropriate option (Correct Answer)
D. Depot medroxyprogesterone injection should be avoided
E. Subdermal implant (etonogestrel) is contraindicated
Explanation: ***Intrauterine device is the most appropriate option***
- **Sodium valproate** is highly **teratogenic**, causing neurodevelopmental delays and major malformations; therefore, the most reliable contraception is required for women of childbearing potential.
- An **Intrauterine Device (IUD)** offers the highest efficacy (Long-Acting Reversible Contraception) and is not affected by drug-drug interactions, ensuring the **Pregnancy Prevention Programme** requirements are met.
*Combined oral contraceptive pill is safe and effective*
- While not pharmacologically contraindicated because valproate is not a strong **enzyme inducer**, the **typical-use failure rate** of the pill is too high given the extreme risks of valproate exposure.
- Use of the COCP/POP is generally discouraged as a standalone method in patients on valproate due to the risk of **unplanned pregnancy**.
*Progesterone-only pill will provide adequate contraception*
- The **Progesterone-only pill (POP)** is highly user-dependent and has a higher failure rate compared to **LARC** methods like the IUD.
- In the context of **valproate therapy**, methods requiring daily compliance are less suitable than long-acting options to prevent **teratogenicity**.
*Depot medroxyprogesterone injection should be avoided*
- This statement is incorrect as the **Depot medroxyprogesterone injection** is a reliable long-acting contraceptive that is not affected by valproate.
- It is actually a recommended option for women on valproate if they prefer it over an **intrauterine device** or implant.
*Subdermal implant (etonogestrel) is contraindicated*
- The **subdermal implant** is not contraindicated; it is actually a highly effective **LARC** method suitable for patients on valproate.
- Since valproate is not an **enzyme-inducing** anti-epileptic drug, it does not reduce the contraceptive efficacy of the etonogestrel implant.
Question 30: A 4-year-old boy with newly diagnosed type 1 diabetes is being started on insulin therapy. His weight is 16 kg. The diabetes team plans to commence a basal-bolus regimen. Using a standard starting total daily insulin dose of 0.5 units/kg/day, with 50% as basal insulin and 50% divided between three meals, what is the appropriate starting dose of rapid-acting insulin for each main meal?
A. 1.3 units (Correct Answer)
B. 2 units
C. 2.7 units
D. 4 units
E. 8 units
Explanation: ***1.3 units***- The **Total Daily Dose (TDD)** is calculated as 16 kg × 0.5 units/kg/day, equaling **8 units** of insulin per day.- The **bolus insulin** total is 50% of the TDD (4 units), which, when divided by **three meals**, results in approximately **1.3 units** per meal.*2 units*- This dose would lead to a total of 6 units of rapid-acting insulin per day (2 units × 3 meals), which exceeds the calculated **50% bolus allocation** of 4 units.- Administering 2 units per meal would disproportionately increase **prandial insulin** relative to basal insulin.*2.7 units*- This calculation incorrectly divides the **entire Total Daily Dose (8 units)** across the three meals, neglecting the crucial need for **basal insulin**.- Such a regimen would leave the patient without **long-acting insulin coverage**, leading to uncontrolled blood glucose between meals and overnight.*4 units*- This amount represents the **total daily bolus insulin** (50% of TDD) or the total daily basal insulin, not the dose for a single meal.- Administering 4 units of rapid-acting insulin at each of the three main meals would result in 12 units of bolus insulin, significantly **exceeding the TDD** of 8 units.*8 units*- This is the **Total Daily Dose (TDD)** for the patient, representing the total insulin needed over 24 hours.- Giving 8 units of rapid-acting insulin for a single meal would cause severe and potentially life-threatening **hypoglycemia**.
